A recent report from MarketsAndMarkets projected that the global gastric cancer market accounted for USD 3.01 billion in 2023 and is expected to reach USD 18.43 billion by 2034 with a CAGR of 17.92% ...

The Phase 1 trial is a randomized, double-blind, placebo-controlled study of single and multiple ascending doses of oral SCY-247 in approximately 100 healthy subjects. The primary endpoint is safety ...

As 2024 draws to a close, we explore five stocks to buy for a new year that promises opportunity alongside uncertainty ...

Biogen (BIIB) closed near a 52-week low of $150.03. The stock trades at a discount because the biotech firm lacks growth ...

Survival Rate and 37% Reduction in Risk of Death Multiple Patients with Complete Responses (CRs) and/or Partial Response (PR) ...

CHRISTMAS is a very busy time of the year for the NHS but it is also a pioneering anniversary when numerous life-saving medical discoveries ...

Duality Biologics and GSK enter into an exclusive option agreement to exploit gastrointestinal cancer target, DB-1324 - On December ...

There is no doubt that doctors and hospitals sometimes push more treatments on people than needed, and insurers’ role is to push back and prevent overspending. The FBI estimates fraud and abuse amount ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

With that in mind, GSK is partnering with developer Reef and investor UBS Asset Management to build a 1.4M SF, £900M life ...